Oxygen
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OXYGEN, USP | — | 2013-06-16 | fda.gov ↗ |
Trials 123 · started per year
Also used as a comparator or background therapy in 98 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06740305 Background | May → Aug 2025 | decompression sickness | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT02473354 Background | Apr 2015 → Apr 2018 | respiratory underresponsiveness to hypoxia and hypercapnia | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT01298921 Comparator | Jan 2011 → Jun 2012 | cluster headache syndrome | Geisinger Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT01157624 Comparator | May → Oct 2010 | — | University of Malaya | Completed | No outcome recorded |
| Phase 1 | NCT00474825 Comparator | Jul 2007 → Feb 2011 | head and neck cancer, squamous cell carcinoma | National Baromedical Services | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02065947 Comparator | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01261377 Comparator | Nov 2010 → Sep 2011 | chronic obstructive pulmonary disease | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06043440 Comparator | Oct 2023 → Nov 2027 expected | Down syndrome, obstructive sleep apnea syndrome | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04378426 Background | Oct 2021 → Aug 2022 | post-traumatic stress disorder | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 2 | NCT04398290 Background | Dec 2020 → Jun 2021 | COVID-19, respiratory failure | Roger Alvarez | Withdrawn | No outcome recorded |
| Phase 2 | NCT03841084 Comparator | Sep 2019 → Jun 2023 | heart failure | Australian and New Zealand Intensive Care Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT04207593 Comparator | Apr 2019 → Jan 2023 | chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT02949531 Comparator | Nov 2016 → Feb 2017 | heart failure | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01413841 Comparator | Jul 2011 → Jun 2012 | coronary artery disorder | Region Skane | Completed | No outcome recorded |
| Phase 2 | NCT00971607 Comparator | May 2009 → Dec 2013 | acute myocardial infarction | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT00566007 Comparator | Dec 2008 → Mar 2014 | lumbar disk disease | Kovacs Foundation | Terminated | No outcome recorded |
| Phase 2 | NCT00410150 Comparator | Apr 2006 → Dec 2007 | status asthmaticus | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05613218 Comparator | Feb 2024 → Feb 2026 | heart failure, pulmonary edema | Copenhagen University Hospital, Hvidovre | Completed | No outcome recorded |
| Phase 2/3 | NCT01990404 Comparator | Jul 2013 → Dec 2015 | — | University Hospital, Toulouse | Terminated | No outcome recorded |
| Phase 2/3 | NCT01659723 Comparator | Aug 2012 → Aug 2018 | radiation cystitis | Göteborg University | Completed | No outcome recorded |
| Phase 2/3 | NCT00515281 Background | May 2008 → Jun 2023 | bronchopulmonary dysplasia, intracerebral hemorrhage, periventricular leukomalacia | University of Chicago | Terminated | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT07262008 Comparator | Feb 2026 → Feb 2027 expected | major depressive disorder | Women's College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05343754 Comparator | Jun 2022 → Jan 2024 | pyoderma gangrenosum | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT05126459 Background | Feb 2022 → Apr 2023 | anxiety, dental caries | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT05335109 Comparator | Jan 2022 → Jan 2024 | ischemic stroke | Negovsky Reanimatology Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03745898 Comparator | Apr 2019 → Jun 2022 | central sleep apnea syndrome, heart failure | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03728894 Comparator | Nov 2018 → Jan 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 3 | NCT03102827 Comparator | Feb 2017 → Mar 2018 | congestive heart failure | Heart and Diabetes Center North-Rhine Westfalia | Terminated | No outcome recorded |
| Phase 3 | NCT02439866 Comparator | Feb 2014 → Jul 2015 | non-arteritic anterior ischemic optic neuropathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01787110 Comparator | Apr 2013 → Dec 2016 | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT02424773 Background | Nov 2012 → Nov 2014 | acute respiratory failure, immunodeficiency disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01155310 Comparator | May 2010 → Oct 2013 | chronic obstructive pulmonary disease | Air Liquide | Terminated | No outcome recorded |
| Phase 3 | NCT00643357 Background | Mar 2008 → Jan 2009 | — | Air Liquide | Withdrawn | No outcome recorded |
| Phase 3 | NCT00392522 Background | Nov 2006 → ? | — | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 3 | NCT00219713 Background | Mar 2000 → Dec 2004 | — | Poitiers University Hospital | Terminated | No outcome recorded |
| Phase 430 trials | ||||||
| Phase 4 | NCT07210606 Comparator | Oct 2026 → Jun 2030 expected | central sleep apnea syndrome | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07186634 Comparator | Apr 2026 → Dec 2035 expected | — | Monash University | Recruiting | No outcome recorded |
| Phase 4 | NCT07387315 Background | Feb → Nov 2026 expected | overactive bladder | TriHealth Inc. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05627024 Comparator | Jan 2023 → Jul 2024 | middle lobe syndrome | China Medical University, China | Completed | No outcome recorded |
| Phase 4 | NCT05052125 Comparator | Dec 2021 → Aug 2024 | chronic obstructive pulmonary disease | Mikkel Brabrand | Terminated | No outcome recorded |
| Phase 4 | NCT04957368 Comparator | Nov 2021 → Feb 2024 | major depressive disorder | Unity Health Toronto | Completed | No outcome recorded |
| Phase 4 | NCT04118387 Comparator | Jan 2021 → Dec 2026 expected | central sleep apnea syndrome | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT03941990 Background | Nov 2019 → Apr 2020 | anxiety | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 4 | NCT03840486 Comparator | Sep 2019 → Oct 2023 | — | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04133740 Comparator | Oct 2018 → Jul 2019 | acute lung injury | Aalborg University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03441204 Comparator | May 2018 → Apr 2022 | respiratory failure | Skane University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03491644 Comparator | Apr → Jul 2018 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT03366857 Comparator | Dec 2017 → Dec 2019 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT03228628 Background | Oct 2017 → Jun 2018 | anxiety | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 4 | NCT03174002 Comparator | Jun 2017 → Nov 2020 | acute respiratory failure | Aalborg University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02378545 Comparator | Oct 2015 → Oct 2016 | infectious disease with sepsis | University Hospital Plymouth NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT02273830 Comparator | Sep 2015 → Oct 2017 | chronic obstructive pulmonary disease | Jtarrega | Completed | No outcome recorded |
| Phase 4 | NCT02321072 Comparator | Feb 2015 → Jan 2019 | autoinflammatory syndrome | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT02286063 Comparator | Aug 2014 → Jan 2018 | pulmonary fibrosis | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02243826 Background | Jul 2014 → Oct 2015 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 4 | NCT02150590 Comparator | Jun → Oct 2014 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT02143609 Comparator | May → Oct 2014 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT02573987 Comparator | Mar 2013 → Apr 2015 | — | Hospital St. Joseph, Marseille, France | Completed | No outcome recorded |
| Phase 4 | NCT01087229 Background | Mar 2010 → Sep 2013 | frozen shoulder | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00637936 Comparator | Mar → Aug 2008 | — | University of Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00547209 Background | Oct 2007 → Nov 2009 | — | Hopital Foch | Completed | No outcome recorded |
| Phase 4 | NCT00439075 Comparator | Oct 2006 → Apr 2008 | pulmonary edema | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00364741 Comparator | Oct 2006 → Oct 2008 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00431691 Comparator | Sep 2006 → Dec 2007 | escherichia coli infection, retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00732537 Comparator | Mar 1999 → Jun 2005 | persistent fetal circulation syndrome, respiratory failure | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase not applicable33 trials | ||||||
| — | NCT07315594 Comparator | Jul 2026 → Jun 2029 expected | — | University of Alberta | Not yet recruiting | No outcome recorded |
| — | NCT06108791 Comparator | Apr 2025 → Jun 2026 | — | Assiut University | Completed | No outcome recorded |
| — | NCT06273319 Comparator | Mar → May 2024 | stomach disorder | Inonu University | Unknown | No outcome recorded |
| — | NCT05414370 Comparator | Dec 2022 → Dec 2024 | acute lung injury | Belfast Health and Social Care Trust | Unknown | No outcome recorded |
| — | NCT04307615 Comparator | Jul 2022 → Jul 2027 expected | pulmonary edema | Dalarna County Council, Sweden | Recruiting | No outcome recorded |
| — | NCT03825835 Comparator | Jun 2022 → Sep 2027 expected | neurodevelopmental disorder, pulmonary immaturity, respiratory distress syndrome in premature infants | University of Alberta | Recruiting | No outcome recorded |
| — | NCT05480566 Background | Jun 2022 → Dec 2023 | chronic obstructive pulmonary disease | Hasselt University | Terminated | No outcome recorded |
| — | NCT04824703 Comparator | Apr 2021 → May 2023 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT05218564 Comparator | Feb 2020 → Mar 2022 | chronic obstructive pulmonary disease | Fondazione Don Carlo Gnocchi ETS | Unknown | No outcome recorded |
| — | NCT03956264 Comparator | Sep 2019 → Jul 2020 | cardiac valvular defect | CMC Ambroise Paré | Completed | No outcome recorded |
| — | NCT07024914 Comparator | Sep 2019 → Dec 2025 overdue | chronic obstructive pulmonary disease | George Papanicolaou Hospital | Active not recruiting | No outcome recorded |
| — | NCT03683082 Comparator | Jun 2018 → Jun 2019 | pulmonary arterial hypertension | George Papanicolaou Hospital | Unknown | No outcome recorded |
| — | NCT03688334 Comparator | Jun 2018 → Jun 2019 | idiopathic pulmonary fibrosis | George Papanicolaou Hospital | Completed | No outcome recorded |
| — | NCT03239678 Comparator | Aug → Dec 2017 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT02741284 Comparator | Jun 2016 → Jun 2017 | perinatal asphyxia, placental insufficiency | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02534012 Background | May 2016 → Apr 2022 | — | Makassed General Hospital | Unknown | No outcome recorded |
| — | NCT02752490 Comparator | Apr → Jul 2016 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT02460055 Comparator | Mar → Jun 2016 | lung disorder | Baylor College of Medicine | Withdrawn | No outcome recorded |
| — | NCT03020212 Comparator | Feb 2016 → Jan 2025 | chronic obstructive pulmonary disease | Fundación Neumologica Colombiana | Completed | No outcome recorded |
| — | NCT02410707 Background | Feb 2015 → Feb 2018 | abscess | Albert Einstein Healthcare Network | Completed | No outcome recorded |
| — | NCT02355678 Background | Jan → Aug 2015 | — | Makassed General Hospital | Completed | No outcome recorded |
| — | NCT02233634 Comparator | Oct 2014 → Nov 2017 | coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT02236260 Background | Sep 2014 → Jun 2017 | Parkinson disease | Nantes University Hospital | Completed | No outcome recorded |
| — | NCT02244957 Comparator | Sep 2014 → Feb 2017 | chronic obstructive pulmonary disease, obstructive sleep apnea syndrome | University of California, San Diego | Completed | No outcome recorded |
| — | NCT01734954 Background | Apr → Aug 2013 | — | CES University | Unknown | No outcome recorded |
| — | NCT01751971 Comparator | Nov 2012 → Jul 2016 | sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01722422 Comparator | Oct 2012 → Sep 2014 | adult acute respiratory distress syndrome, infectious disease with sepsis | University Hospital, Angers | Terminated | No outcome recorded |
| — | NCT01636999 Background | Sep 2012 → Sep 2014 | — | West Penn Allegheny Health System | Withdrawn | No outcome recorded |
| — | NCT01611064 Comparator | Feb → Jun 2012 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT01511627 Comparator | Jan → Jul 2012 | — | University of Saskatchewan | Withdrawn | No outcome recorded |
| — | NCT02150434 Comparator | Nov 2009 → May 2012 | chronic obstructive pulmonary disease | Laval University | Completed | No outcome recorded |
| — | NCT00874172 Background | Oct 2009 → Oct 2012 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01448889 Comparator | Sep 2009 → Sep 2012 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 224 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxygen | “Patients were randomized to receive either usual care, including conventional optimal treatment with furosemide, oxygen, and high-dose boluses of isosorbide dinitrate plus...” PMID 20825901 ↗ May 2010183“All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.” NCT02236260 ↗ “Patients are randomized between two daily durations of oxygen used in current clinical practice: LTOT 24 h/day (intervention) or 15 h/day (control).” NCT03441204 ↗ “Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.” NCT02534012 ↗ “Patients will be randomly assigned to receive either 100% oxygen by mask (treated group) or breath room air (control group).” NCT01448889 ↗ “administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation” NCT05126459 ↗ “Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%.” NCT02355678 ↗ “Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes” NCT01355809 ↗ “the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air” NCT06108791 ↗ “60% nitrous oxide combined with 40% oxygen for ventilation” NCT00547209 ↗ “Maintenance of anesthesia with sevoflurane, oxygen and air” NCT01511627 ↗ “Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen” NCT03956264 ↗ “a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen” NCT03483194 ↗ “Participants breathe 60% oxygen during exercise” NCT03800017 ↗ “paracetamol 1 g per os nasal oxygen therapy” NCT00874172 ↗ “Oxygen” NCT02150434 ↗ |
| Known as | 02 or Oxygen | “02 or Oxygen” NCT01847755 ↗ |
| Known as | Air/Oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01155310 ↗ |
| Known as | Dioxygen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | E-948 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | Equimolar Mixture of Nitrogen Protoxide and Oxygen | “Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia” NCT00822224 ↗ |
| Known as | HBO2 | “The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen).” NCT01611194 ↗1“Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group” NCT05173818 ↗ |
| Known as | Hyperbaric oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02407028 ↗ |
| Known as | Hyperbaric Oxygen Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02363959 ↗ |
| Known as | INS NO.948 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | INS-948 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | Liquid oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05414370 ↗ |
| Known as | Medical Grade Oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01731015 ↗ |
| Known as | Medical Oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02895724 ↗ |
| Known as | Medicinal oxygen air liquide sante | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | MEOPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822224 ↗ |
| Known as | Molecular oxygen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | NBO | “Subjects will be consented to inhale either Normobaric Oxygen (NBO) or Room air for 30 minutes at the start of their migraine attacks.” NCT01542307 ↗ |
| Known as | Normobaric Oxygen | “Subjects will be consented to inhale either Normobaric Oxygen (NBO) or Room air for 30 minutes at the start of their migraine attacks.” NCT01542307 ↗ |
| Known as | O(2) | “All patients were tested with each of three agents (80 ppm iNO, 100% O(2), combination of 80 ppm iNO/100% O(2)) in three 10-min treatment periods, and hemodynamic measurements obtained.” PMID 20405117 ↗ Apr 2010 |
| Known as | Oxygen 93 percent | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | OXYGEN COMPONENT OF RNS-60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | Oxygen molecule | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | Oxygen supplementation | “Drug: Oxygen supplementation” NCT03683082 ↗ |
| Known as | OXYGEN THERAPY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06273319 ↗ |
| Known as | Oxygen/nitrous oxide equimolar mix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02573987 ↗ |
| Known as | Oxygenium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234886 ↗ |
| Known as | Oxygène | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00643786 ↗ |
| Known as | PL 15929/005 | “The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK.” NCT02286063 ↗ |
| Known as | Premixed 50% nitrous oxide and oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01990404 ↗ |
| Known as | SAUERSTOFF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04094285 ↗ |
| Known as | supplemental oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01734954 ↗ |
| Action | Inhibit | “100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture...” NCT02185118 ↗ |
| Modality | Other / unclassified | “oxygen inhalation via HFNC” PMID 22147778 ↗ Dec 2011 |
| Route | Other | “Patients also undergo HBOT once daily, 5 days a week, for 90 days (60 treatments total).” NCT00087815 ↗ |